$NTRA

ROSENMAN HERM sold $4.1M of NTRA

ROSENMAN HERM sold 16,530 shares of Natera, Inc. (NTRA) at $250.00 ($4.13M total) on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROSENMAN HERM
Published Jun 27, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 27, 2026, 1:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosed sale is a director open-market transaction executed under a pre-arranged 10b5-1 plan, which typically limits inference about management’s forward outlook.

02

Market read

This provides incremental insider-activity information but no new operational, financial, or regulatory catalyst.

03

What to watch

Traders may over-weight the sale size; without additional context (e.g., total insider holdings trend, other concurrent filings), the signal is weak.

Relevance 5/10Novelty 4/10Timing: latest Form 4 filed late June; sale dated 2026-06-24

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera (NTRA) disclosed a director open-market sale of 16,530 shares at $250/share under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more about sentiment/positioning than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which generally dampens interpretability versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than a view on near-term prospects.

Key entities

  • Natera, Inc.

    Subject of the Form 4 insider transaction; director sold 16,530 shares at $250/share.

  • ROSENMAN HERM

    Director who reported the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMedAI 8/10

Natera, Inc.: Signatera Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

Natera (NTRA) presented data from the ESMO Congress 2026, showcasing its Signatera assay in 25 abstracts, including 9 oral presentations. The VOLGA trial in bladder cancer showed that Signatera ctDNA dynamics predicted event-free survival, with persistently negative patients having a 24-month EFS rate of 91%. Additional studies in lung, endometrial, and breast cancer were also highlighted, demonstrating the potential of ctDNA testing in guiding treatment decisions.

$NTRAMed

Natera technology featured in 25 abstracts at ESMO congress

Natera Inc. (NTRA) presented cancer study results at the ESMO Congress 2026, with its technology featured in 25 abstracts. Key findings included high event-free survival rates in bladder cancer, high ctDNA detection in lung cancer, and predictive value in endometrial cancer. Studies also covered colorectal and gastroesophageal cancers.

$NTRALow

Natera, Inc. (NTRA) ctDNA Dynamics Predict EFS in MIBC

Natera (NTRA) reported phase III VOLGA trial data showing Signatera ctDNA dynamics predict event-free survival in MIBC, with 24-month EFS rates of 91% for persistently negative, 81% for cleared pre-surgery, and 55% for persistently positive. The company noted this as late-cycle validation for Signatera's role in MRD for bladder cancer.

$NTRAMed

Natera stock price target raised to $430 by BTIG on revenue outlook

BTIG raised its price target on Natera (NTRA) to $430 from $320, citing strong revenue growth expectations. The firm anticipates a 7% revenue beat in Q3 and projects 318,000 Signatera tests, up 57% YoY. Natera's stock is up 77% YTD and 111% over the past year, but is considered overvalued by InvestingPro. Recent Q2 revenue of $753M exceeded expectations, and multiple analysts have raised price targets.